GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from China’s Frontier Biotechnologies. | GSK is continuing to bolster its siRNA ...
Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent ...
Gilead Sciences will pay an 80% premium to Arcellx’s closing price Friday to acquire the cancer drug developer.
Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...
This biotech powerhouse could maintain its strength for the long term.
Investor's Business Daily on MSN
This rare disease biotech name teases around a buy point
This company develops treatments for rare genetic diseases. It partners with Biogen.
AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.
As of Monday, February 23, Fortress Biotech, Inc.’s FBIO share price has surged by 18.42%, which has investors questioning if ...
Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...
Celebrate International Day of Women and Girls in Science 2026 by discovering some of the most influential women shaping biotech today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results